Avascular Necrosis Market Size to Surpass USD 0.881 Billion By 2032

Pune, India, June, 2022/press release/- Market Research Future Published a Cooked Research Report on Global Avascular Necrosis Market Research Report.

Avascular necrosis (AVN) is a common cause of musculoskeletal disability and has placed itself as a foremost challenge both therapeutically and diagnostically in recent years. The incidence of avascular necrosis globally has seen a significant rise in recent times. Trauma is identified as the most common reason of avascular necrosis; however, nontraumatic AVN is found to be occurring usually in younger adults. 

The Avascular Necrosis Market is expected to reach USD 0.881 Billion by 2032 at 6.50% CAGR during the forecast period 2023-2032. The avascular necrosis market globally is motivated by the growing occurrence of bone diseases such as osteoarthritis and osteoporosis together with the mounting cases of alcohol abuse and steroids, and implementation of the medication over surgery by the patients. However, strict regulatory requirements and lack of awareness in a majority of the population may curb the progress of the market in the forecast period.

On the other hand, the rising levels of awareness of the medical condition of avascular necrosis among physicians and patients in these countries is an evident growth promoter of the market. The persons between the ages of 30 to 50 years are usually found to be affected, and males are more generally affected than females. Additionally, the expansions in therapeutic technologies such as gene therapy and stem cell-based osteonecrosis treatment are also anticipated to boost the market’s progress. The primary treatment regimen primarily comprises medications such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) for reducing pain and swelling, cholesterol-lowering drugs, and blood thinners. These drugs might control the symptoms of the disease but are not yet capable of providing far-reaching cure to the condition. Thus, in these cases, surgery becomes the vital treatment for curing avascular necrosis. Though, the original Advanced Therapy Medicinal Products (ATMPs) are projected to boost the market.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Avascular Necrosis Market Research Report

Segmental Analysis

The segments on the basis of type, site, diagnosis, treatment, end-user, and region are used for the segmentation of the avascular necrosis market globally. By type, the market has been segmented non-trauma related avascular necrosis (AVN) and into trauma-related avascular necrosis (AVN). The non-trauma related avascular necrosis segment presently is credited for the major market share and is expected to continue to be extremely productive throughout the assessment period. By site, the segmentation of the market includes knee, hip bone, shoulder, and other. In the year 2017, the hip bone segment was worth USD 508 Mn approximately. By diagnosis, the market has been segmented into biopsy and imaging. The imaging segment at present is attributable for the biggest market share in the year 2017. The treatment segment of the market has comprises of electrical stimulation, medication, gene therapy, and surgery. Among these segments, the oncology segment is anticipated to develop with the peaking CAGR percent during the forecast period. The end user segment the market has been segmented into diagnostic centers, hospitals & clinics, and ambulatory surgical centers. The hospitals & clinics will probably retain its top position by the end of 2024.

Regional Analysis

The region wise segmentation of the market comprises of regions such as Europe, Americas, the Middle East & Africa (MEA) and Asia Pacific (APAC). The Americas region is presently attributed for the chief market share, and the trend is expected to carry on in the foreseeable future. This is attributable to the robust value upheld by the hip bone replacement segment in both the U.S. and other Latin American nations. Furthermore, the medical device industry is one of the principal ventures in the US. The Asia Pacific and European regions are also anticipated to continue its significant growth in various revenue pockets for the avascular necrosis (AVN) market during the forecast period. While the APAC region’s trajectory is mostly directed by factors such as improved equipment and infrastructure and intensifying R&D initiatives to increase the effectiveness and efficacy of new drugs. The increasing demand for reduced cost of treatment procedures in emerging countries such as China and India has improved the demand development of minimally invasive surgeries. These two nations are responsible for almost 40% of the total global population affected with AVN disease. Strict regulatory requirements and absence of awareness in the majority of the population may confine the expansion of the market in the asessment period.

Competitive Analysis

The competitors in the market are also leveraging their competitive benefits to protect their growth in the market. The companies in the market are persistently trying to establish leading market positions through new policies and strategies. The key trends and players have established a positive tone for development. The experienced management in the companies functioning in the market is creating business models which can bring about a productive phase of development. The competitors in the market are trying to succeed commercially by ensuring demand and supply are in balance.

Ethicon Inc., Sanofi SA, Wright Medical Group N.V., Bayer AG, Pfizer Inc., Merck KGaA, Aurobindo Pharma, Eli Lilly and Company, Zimmer Biomet Holdings, Stryker Corporation, Medtronic plc, Boehringer Ingelheim GmbH, Integra LifeSciences Corporation, Smith and Nephew, Grifols SA, and others.